Ganglioglioma Overview

Save information for later
Sign Up

Learn About Ganglioglioma

What is the definition of Ganglioglioma?
A Ganglioglioma is a rare type of brain tumor, accounting for approximately 1% of all brain tumors. Gangliogliomas occur when a single cell in the brain starts to divide into more cells, forming a tumor. This can occur when the cell randomly acquires changes in genes that regulate how a cell divides. Most Gangliogliomas grow slowly and are considered benign. However, up to 10% of Gangliogliomas may grow more rapidly and become malignant, meaning the tumor affects the surrounding brain tissue.
What are the alternative names for Ganglioglioma?
  • Ganglioglioma
  • Mixed cell tumors containing both neural ganglionic cells and neural glial cell components
Who are the top Ganglioglioma Local Doctors?
Elite in Ganglioglioma
Alexander Grote
Elite in Ganglioglioma
Alexander Grote
Marburg An Der Lahn, HE, DE 

Alexander Grote practices in Marburg An Der Lahn, Germany. Mr. Grote is rated as an Elite expert by MediFind in the treatment of Ganglioglioma. His top areas of expertise are Ganglioglioma, Epilepsy, Seizures, Glioma, and Posterior Fossa Decompression.

Elite in Ganglioglioma
Dr. Nicholas Foreman
Hematology | Oncology
Elite in Ganglioglioma
Dr. Nicholas Foreman
Hematology | Oncology

Children's Hospital Colorado

13123 E 16th Ave, 
Aurora, CO 
720-777-1234
Languages Spoken:
English
See accepted insurances

Nicholas Foreman is a Hematologist and an Oncologist in Aurora, Colorado. Dr. Foreman is rated as an Elite provider by MediFind in the treatment of Ganglioglioma. His top areas of expertise are Medulloblastoma, Ganglioglioma, Glioma, and Rhabdoid Tumor.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in Ganglioglioma
Dr. Todd Hankinson
Neurosurgery
Elite in Ganglioglioma
Dr. Todd Hankinson
Neurosurgery
13123 E 16th Ave, 
Aurora, CO 
720-777-1234
Languages Spoken:
English
See accepted insurances

Todd Hankinson is a Neurosurgery provider in Aurora, Colorado. Dr. Hankinson is rated as an Elite provider by MediFind in the treatment of Ganglioglioma. His top areas of expertise are Craniopharyngioma, Ganglioglioma, Brain Tumor, Posterior Fossa Decompression, and Craniectomy.

View All Doctors
What are the latest Ganglioglioma Clinical Trials?
A Phase II Study of Hippocampal-Avoidance Using Proton Therapy in Low-Grade Glioma
A Phase II Study of Hippocampal-Avoidance Using Proton Therapy in Low-Grade Glioma
Enrollment Status: Recruiting
Publish Date: January 07, 2026
Intervention Type: Radiation
Study Phase: Not Applicable

Objective: * To determine the feasibility of HA with proton therapy in suprasellar or midline LGGs. Feasibility will be established if 70% of plans meet the first or second dose constraints shown below. 1. First priority RT dose constraints for bilateral hippocampi: volume receiving 40 CGE (V40CGE) ≤ 25%, dose to 100% of Hippocampus (D100%) ≤ 5CGE. 2. Second priority RT dose constraints for bilateral hippoca...

Match to trials
Find the right clinical trials for you in under a minute
Get started
A Phase I Study of the Treatment of Recurrent Malignant Glioma With rQNestin34.5v.2, a Genetically Engineered HSV-1 Virus, and Immunomodulation With Cyclophosphamide
A Phase I Study of the Treatment of Recurrent Malignant Glioma With rQNestin34.5v.2, a Genetically Engineered HSV-1 Virus, and Immunomodulation With Cyclophosphamide
Who is this study for: Patients with recurrent malignant glioma
Enrollment Status: Recruiting
Publish Date: July 08, 2025
Intervention Type: Procedure, Drug
Study Drugs: rQNestin, Cyclophosphamide
Study Phase: Phase 1

Summary: This research study is evaluating an investigational drug, an oncolytic virus called rQNestin34.5v.2. This research study is a Phase I clinical trial, which tests the safety of an investigational drug and also tries to define the appropriate dose of the investigational drug as a possible treatment for this diagnosis of recurrent or progressive brain tumor.

View All Clinical Trials
Who are the sources who wrote this article ?

Published Date: May 11, 2022
Published By: Genetic and Rare Diseases Informnation Center